Ọnwụnwa ụlọọgwụ ọhụrụ maka ọgwụgwọ ọrịa kansa prostate

Hinova Pharmaceuticals Inc., ụlọ ọrụ biopharmaceutical nke ụlọ ọgwụ lekwasịrị anya n'ịzụlite ọgwụgwọ ọhụụ maka ọrịa kansa na ọrịa metabolic site na teknụzụ mmebi protein ezubere iche, kwupụtara na onye ọrịa mbụ nwere ọrịa kansa prostate na-eguzogide metastatic castration (mCRPC) enwetala nke ọma na usoro nke mbụ. Nnwale ụlọ ọgwụ nke HP518, onye na-ahọrọ nke ukwuu na ọnụ nke na-eme ihe na-eme ihe na-eme ihe na-eme ihe na-achọ ihe na-anabata androgen (AR). Ọmụmụ ihe na-emepe emepe na-aga n'ihu n'Apase I n'Australia ga-enyocha nchekwa, pharmacokinetics, na mgbochi tumor nke HP518 na ndị ọrịa nwere mCRPC.

Print Friendly, PDF & Email

Achọpụtara ma mepụta HP518 site na ikpo okwu nchọpụta ọgwụ na-emebi protein ezubere iche nke Hinova. Ọ nwere ikike imeri nguzogide ọgwụ nke ọrịa kansa prostate n'ihi ụfọdụ mmụgharị AR a kapịrị ọnụ.

Chimeric degraders bụ obere ụmụ irighiri ihe na-arụ ọrụ nke na-akwalite mmebi nke protein ndị e lekwasịrị anya nwere ike dị elu na nhọrọ dị elu. Nkà na ụzụ a nwere ike irube ebumnobi ndị na-abụghị ọgwụ na imeri okwu mgbochi ọgwụ nke obere ọgwụ molekul ọdịnala.

Yuanwei Chen, Ph.D., Onye isi ala na onye isi oche nke Hinova kwuru, "Nke a bụ ihe ịrịba ama dị ịrịba ama na ọganihu anyị na-agba mbọ site na nchọpụta ọgwụ ọjọọ ruo na ọmụmụ ụlọ ọgwụ." "Anyị nwere obi ụtọ maka ya ma raara onwe anyị nye iwetara ndị ọrịa nhọrọ ọgwụgwọ ọhụrụ n'ụwa niile!"

Site na ikpo okwu nchọta ọgwụ na-emebi protein ezubere iche, Hinova nwere ike nyochaa ọrụ mmebi protein ngwa ngwa wee rụzuo nhazi nke ọma na nkwalite nke ndị na-emebi chimeric. Ọzọkwa, Hinova nwere ahụmahụ miri emi na njikwa kemịkalụ n'ichepụta ogige Chimeric degrader.

Print Friendly, PDF & Email
Enweghị akara ọ bụla maka post a.

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment